Benefit of this study
Benefits of this study

At the end of this study people will be able to know

1. Regulated low dose of secretagouges (glibenclamide) is able to do the glycemic control. This will, along with pts education, reduce the chance of hypoglycemia which is common and sometimes fatal.

2. Metformin (MET) though has potentiality to produce lactic acidosis but it not common in selected cases in high doses.

3. Pioglitazone (a TZD derivative) has the less chance to increase SGPT in low dose which is a adverse effect to withdraw the drug during therapy (if it s more than 3 times of ULN)

4. Dose of insulin can lowered in insulin naïve t2dm pts. It is cost effective and safe.

5. Which one is the lipid friendly insulin sensitizer